Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease." Memantine has negligible benefits in mild to moderate Alzheimer's disease

David S. Knopman

Research output: Contribution to journal › Comment/debate › peer-review

5 Scopus citations

Fingerprint

Dive into the research topics of 'Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease." Memantine has negligible benefits in mild to moderate Alzheimer's disease'. Together they form a unique fingerprint.